RPG Life Sciences Limited (BOM:532983)

Market Cap	32.66B -13.1%
Revenue (ttm)	6.74B +5.7%
Net Income	2.03B +156.1%
EPS	122.51 +156.1%
Shares Out	n/a
PE Ratio	16.12
Forward PE	n/a
Dividend	24.00 (1.22%)
Ex-Dividend Date	Jun 27, 2025

Volume	92
Average Volume	1,072
Open	1,987.00
Previous Close	2,006.80
Day's Range	1,960.00 - 2,008.40
52-Week Range	1,772.05 - 2,715.90
Beta	n/a
RSI	34.62
Earnings Date	Jan 27, 2026

About RPG Life Sciences

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology...

• Industry: Pharmaceutical Preparations
• Founded: 1968
• Employees: 1,331
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532983

Financial Performance

In fiscal year 2025, RPG Life Sciences's revenue was 6.53 billion, an increase of 12.26% compared to the previous year's 5.82 billion. Earnings were 1.83 billion, an increase of 109.03%.